CSF2 and respiratory failure: However, a large, double-blind, randomized trial of otilimab (65), in which the primary endpoint was survival free from respiratory failure at Day 28, and a small, double-blind, randomized trial of mavrilimumab, in which the primary endpoint was proportion alive and off supplemental oxygen at Day 14 (66), did not show a survival benefit for the GM-CSF inhibitors compared to placebo.